G4型髓母细胞瘤患儿预后影响因素及生存状况分析

doi:10.12372/jcp.2023.22e1634

Abstract

Abstract:

Objective To investigate the survival status and prognostic factors of group 4 medulloblastoma (MB) in children. Methods The clinical data of children with group 4 MB admitted to the Department of Pediatrics from May 2016 to August 2020 (follow-up until August 2022) were retrospectively analyzed. The Kaplan-Meier method was used to calculate the overall survival (OS) rate and progression-free survival (PFS) rate. Log-rank test was used to compare the difference in survival rate between groups, and Cox regression model was used to analyze the factors affecting prognosis. Results A total of 145 children (106 boys and 39 girls) with group 4 MB were included, and the median age of diagnosis was 7.5 (5.7-9.6) years old. There were 91 children in M₀ stage and 54 children in M₊ stage (1 in M₁ stage, 12 in M₂ stage and 41 in M₃ stage). The pathologic types were classic in 127 cases, desmoplastic/nodular (DN) in 8 cases, anaplastic/large cell (LC/A) in 8 cases, extensive nodularity (EN) in 1 case, and none of somatotype (NOS) in 1 case. The median follow-up time was 47.9 (36.5-59.3) months, and 37 children had tumor recurrence. The 5-year OS and PFS rates were (80.8±3.4) % and (55.4±4.7) %, respectively. Cox regression analysis indicated that M₊ stage, MYCN amplification and Chr12p+ variation were independent risk factors for prognosis (P<0.05). Conclusions Group 4 MB children with M₊ stage or MYCN amplification have a relatively poor prognosis. Chr12p + may be related to the prognosis of children, but it needs to be confirmed by clinical studies with larger samples.

Key words: group 4 medulloblastoma, prognosis, influencing factor, child

WU Yuefang, SUN Yanling, WU Wanshui, DU Shuxu, LI Miao, SUN Liming. Analysis of prognostic factors and survival status of group 4 medulloblastoma in children[J].Journal of Clinical Pediatrics, 2023, 41(9): 686-691.

Figures/Tables 2

References 21

[1]	Northcott PA, Robinson GW, Kratz CP, et al. Medulloblastoma[J]. Nat Rev Dis Primers, 2019, 5(1): 11. doi: 10.1038/s41572-019-0063-6 pmid: 30765705
[2]	Vladoiu MC, El-Hamamy I, Donovan LK, et al. Childhood cerebellar tumours mirror conserved fetal transcriptional programs[J]. Nature, 2019, 572(7767): 67-73. doi: 10.1038/s41586-019-1158-7
[3]	Orr BA. Pathology, diagnostics, and classification of medulloblastoma[J]. Brain Pathol, 2020, 30(3): 664-678. doi: 10.1111/bpa.v30.3
[4]	Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015[J]. Neuro Oncol, 2018, 20(suppl 4): 1-86. doi: 10.1093/neuonc/nox229
[5]	Cotter JA, Hawkins C. Medulloblastoma: WHO 2021 and beyond[J]. Pediatr Dev Pathol, 2022, 25(1): 23-33. doi: 10.1177/10935266211018931
[6]	Suk Y, Gwynne WD, Burns I, et al. Childhood medullo-blastoma: an overview[J]. Methods Mol Biol, 2022, 2423: 1-12.
[7]	Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups[J]. Acta Neuropathol, 2011, 121(3):381-396. doi: 10.1007/s00401-011-0800-8 pmid: 21267586
[8]	Miranda Kuzan-Fischer C, Juraschka K, Taylor MD. Medulloblastoma in the molecular era[J]. J Korean Neurosurg Soc, 2018, 61(3): 292-301. doi: 10.3340/jkns.2018.0028
[9]	Lafay-Cousin L, Baroni L, Ramaswamy V, et al. How do we approach the management of medulloblastoma in young children?[J]. Pediatr Blood Cancer, 2022, 69(10): e29838. doi: 10.1002/pbc.v69.10
[10]	Beccaria K, Padovani L, Bouchoucha Y, et al. Current treatments of medulloblastoma[J]. Curr Opin Oncol, 2021, 33(6): 615-620. doi: 10.1097/CCO.0000000000000788 pmid: 34482338
[11]	Baliga S, Gandola L, Timmermann B, et al. Brain tumors: medulloblastoma, ATRT, ependymoma[J]. Pediatr Blood Cancer, 2021, 68 Suppl 2: e28395.
[12]	Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technique for cerebelar medulloblastomas[J]. Radiology, 1969, 93(6):1351-1359. doi: 10.1148/93.6.1351 pmid: 4983156
[13]	Khatua S, Song A, Citla Sridhar D, et al. Childhood medulloblastoma: current therapies, emerging molecular landscape and newer therapeutic insights[J]. Curr Neuropharmacol, 2018, 16(7): 1045-1058. doi: 10.2174/1570159X15666171129111324 pmid: 29189165
[14]	von Bueren AO, von Hoff K, Pietsch T, et al. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology[J]. Neuro Oncol, 2011, 13(6): 669-679. doi: 10.1093/neuonc/nor025
[15]	Fuller CE, Jones DTW, Kieran MW. New classification for central nervous system tumors: implications for diagnosis and therapy[J]. Am Soc Clin Oncol Educ Book, 2017, 37: 753-763. doi: 10.14694/EDBK_175088 pmid: 28561665
[16]	Hay JL, Atkinson TM, Reeve BB, et al. Cognitive interviewing of the US national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J]. Qual Life Res, 2014, 23(1): 257-269. doi: 10.1007/s11136-013-0470-1 pmid: 23868457
[17]	Shih DJ, Northcott PA, Remke M, et al. Cytogenetic prognostication within medulloblastoma subgroups[J]. J Clin Oncol, 2014, 32(9): 886-896. doi: 10.1200/JCO.2013.50.9539 pmid: 24493713
[18]	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants[J]. J Clin Oncol, 2011, 29(11): 1408-1414. doi: 10.1200/JCO.2009.27.4324 pmid: 20823417
[19]	Pietsch T, Schmidt R, Remke M, et al. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort[J]. Acta Neuropathol, 2014, 128(1): 137-149. doi: 10.1007/s00401-014-1276-0 pmid: 24791927
[20]	Robinson GW, Rudneva VA, Buchhalter I, et al. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial[J]. Lancet Oncol, 2018, 19(6): 768-784. doi: S1470-2045(18)30204-3 pmid: 29778738
[21]	Schwalbe EC, Lindsey JC, Nakjang S, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study[J]. Lancet Oncol, 2017, 18(7): 958-971. doi: S1470-2045(17)30243-7 pmid: 28545823

项目	例数	3年OS率/%	χ²值	P	3年PFS率/%	χ²值	P
性别			0.79	0.376		1.63	0.201
男	106	87.7±3.2			60.9±4.8
女	39	82.1±6.1			71.7±7.2
手术范围			0.02	0.882		1.43	0.233
GTR	103	87.3±3.3			61.7±4.8
NTR/STR	42	83.3±5.8			68.9±7.2
分期			10.96	0.001		13.02	<0.001
M₀	91	92.3±2.8			74.0±4.7
M₊	54	75.9±5.8			47.3±6.7
病理分型			0.85	0.932		2.33	0.676
CMB	127	86.6±3.0			61.8±4.3
DN	8	87.5±11.7			87.5±11.7
LC/A	8	75.0±15.3			62.5±17.1
EN	1	-			-
NOS	1	-			-
染色体变异
有MYCN+	11	72.7±13.4	6.26	0.012	36.4±14.5	7.48	0.006
无MYCN+	134	87.3±2.9	6.26	0.012	66.2±4.1	7.48	0.006
有Chr2p+	6	83.3±15.2	1.18	0.277	50.0±20.4	0.32	0.572
无Chr2p+	139	86.3±2.9	1.18	0.277	64.5±4.1	0.32	0.572
有Chr12p+	7	57.1±18.7	4.12	0.042	14.3±13.2	12.55	<0.001
无Chr12p+	138	87.7±2.8	4.12	0.042	66.4±4.0	12.55	<0.001
有Chr17p+	15	100.0±0.0	3.41	0.065	80.0±10.3	2.98	0.085
无Chr17p+	130	84.6±3.2	3.41	0.065	62.0±4.3	2.98	0.085
有Chr17q+	72	87.5±3.9	0.60	0.440	58.9±5.9	0.88	0.350
无Chr17q+	73	84.9±4.2	0.60	0.440	68.5±5.4	0.88	0.350
有Chr7q+	65	81.5±4.8	2.12	0.145	51.8±6.3	7.06	0.008
无Chr7q+	80	90.0±3.4	2.12	0.145	73.5±5.0	7.06	0.008
有Chr7+	67	82.1±4.7	1.67	0.197	53.3±6.2	5.64	0.018
无Chr7+	78	89.7±3.4	1.67	0.197	72.8±5.1	5.64	0.018
有Chr17+	74	87.8±3.8	0.87	0.350	58.6±5.8	0.98	0.323
无Chr17+	71	84.5±4.3	0.87	0.350	69.0±5.5	0.98	0.323
有Chr18+	16	81.3±9.8	0.02	0.893	68.2±11.8	0.50	0.479
无Chr18+	129	86.8±3.0	0.02	0.893	63.3±4.3	0.50	0.479
有Chr8p-	7	87.5±8.3	0.00	0.962	50.0±12.5	0.89	0.347
无Chr8p-	138	86.0±3.1	0.00	0.962	65.6±4.2	0.89	0.347
有Chr8q-	16	85.7±13.2	0.07	0.795	57.1±18.7	0.11	0.742
无Chr8q-	129	86.2±2.9	0.07	0.795	64.2±4.1	0.11	0.742
有Chr11-	9	77.8±13.9	0.06	0.815	77.8±13.9	1.20	0.274
无Chr11-	136	86.7±2.9	0.06	0.815	62.9±4.2	1.20	0.274
有Chr8-	15	86.7±8.8	0.03	0.853	46.7±12.9	1.46	0.227
无Chr8-	130	86.1±3.0	0.03	0.853	65.9±4.2	1.46	0.227

因素	PFS			OS
因素	HR	95%CI	P	HR	95%CI	P
M₊期	2.89	1.71~4.87	<0.001	4.06	1.77~9.33	0.001
MYCN扩增	3.73	1.79~7.79	<0.001	5.14	1.85~14.28	0.002
Chr12p+	5.28	2.20~12.70	<0.001	3.78	1.09~13.07	0.036

Analysis of prognostic factors and survival status of group 4 medulloblastoma in children

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 21

Related Articles 15

Metrics

Comments

Recommended 0

[1]	ZOU Liping. Childhood encephalopathy: a group of diseases associated with various diseases [J]. Journal of Clinical Pediatrics, 2023, 41(9): 641-643.
[2]	ZHANG Weihua, ZOU Liping, REN Haitao, GUAN Hongzhi. Beware of the pitfalls in diagnosis and treatment of autoimmune encephalitis in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 644-649.
[3]	HOU Chi, CHEN Wenxiong, LIAO Yinting, WU Wenxiao, TIAN Yang, ZHU Haixia, PENG Bingwei, ZENG Yiru, WU Wenlin, CHEN Zongzong, LI Xiaojing. Clinical analysis of autoimmune glial fibrillary acidic protein astrocytopathy in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 656-660.
[4]	YANG Yating, CAI Yuehao, FANG Qiong, CHEN Lang, CHEN Qiaobin, LIN Zhi, WU Feifei, LIN Meng. Clinical analysis of idiopathic and symptomatic occipital lobe epilepsy in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 668-673.
[5]	HOU Ruolin, WU Jing, LI Ling. Pediatric autoimmune encephalitis with brain MRI showing meningeal thickening and enhancement [J]. Journal of Clinical Pediatrics, 2023, 41(9): 674-679.
[6]	XU Quan, YUAN Xiaojun. Diagnosis and treatment characteristics and long-term follow-up of 51 cases of infantile neuroblastoma [J]. Journal of Clinical Pediatrics, 2023, 41(9): 680-685.
[7]	SUN Juan, LI Haiying, JIA Peisheng, WANG Huaili. Clinical analysis of fulminant myocarditis in 12 children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 692-696.
[8]	Reviewer: WANG Chenhui, Reviser: YANG Hui. Research progress on early screening and diagnosis of Crohn's disease in children [J]. Journal of Clinical Pediatrics, 2023, 41(9): 708-714.
[9]	SHEN Nan, DU Bailu. Strategies for the diagnosis, treatment, and management of invasive fungal infections in children with hematologic neoplasms [J]. Journal of Clinical Pediatrics, 2023, 41(8): 571-577.
[10]	XU Beixue, LIU Quanbo. Clinical analysis of 195 children with invasive pulmonary fungal infection [J]. Journal of Clinical Pediatrics, 2023, 41(8): 584-588.
[11]	CHEN Hongyu, LIU Zihao, WANG Heping, LIAO Cuijuan, LI Li, WANG Wenjian, LAI Jianwei. Role of nontypeable Haemophilus influenzae biofilms in chronic pulmonary infection in children [J]. Journal of Clinical Pediatrics, 2023, 41(8): 589-593.
[12]	KANG Lei, GUO Fang, LI Lifang, BAI Xinfeng, CHENG Caiyun, XU Meixian. Value of metagenomic next-generation sequencing in children with visceral leishmaniasis associated with hemolytic histiocytosis [J]. Journal of Clinical Pediatrics, 2023, 41(8): 594-598.
[13]	SUN Zhicai, LIU Yuling, LI Xiaolin, PAN Xiaofen. Clinical analysis of 15 children with primary nephrotic syndrome complicated with adrenal crisis [J]. Journal of Clinical Pediatrics, 2023, 41(8): 610-612.
[14]	WANG Hongxia, PAN Xiang, LU Jun. Report a case of α-ketoadipic aciduria caused by compound heterozygous variant of DHTKD1 gene [J]. Journal of Clinical Pediatrics, 2023, 41(8): 624-628.
[15]	XI Bixin, HU Qun, LIU Aiguo. Research advances of the bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplant in children [J]. Journal of Clinical Pediatrics, 2023, 41(8): 629-633.